Genetics & Environmental Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics & Environmental Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Protein Engineering
Phage Biotechnology Corp. Engages the Bruckner Group To Find a Joint Commercialization Partner for Phage's Portfolio of Recombinant Protein Biopharmaceuticals, Technologies, and Development Platforms
November 22nd, 2007
The Bruckner Group is pleased to announce that Phage Biotechnology Corp. ("Phage") has engaged The Bruckner Group to find a partner to jointly commercialize Phage's portfolio of recombinant biological therapies, the products of Phage's development platforms and technologies. The Phage portfolio includes ten innovative and standard-of-care recombinant proteins, including pegylated human growth hormone, pegylated G-CSF, pegylated interferon alpha, beta interferon, and single-chain antibodies (which will compete with monoclonal antibodies). Phage anticipates its portfolio will produce a revenue stream in the moderate nine-figure range within four years, and a medium to high ten-figure range...
Source: Genetics & Environmental Business Week (2007-11-22)
|
